EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered mesenchymal stromal cells with interleukin-1beta sticky-trap attenuate osteoarthritis in knee joints

Christopher Kim, Biao Li, Sayaka Nakamura, Eric J Neely, Jason S Rockel, Tatiana Oussenko, Puzheng Zhang, Mohit Kapoor, Andras Nagy

Frontiers in Cell and Developmental Biology · 08.04.2025 · 13

DOI: 10.3389/fcell.2025.1559155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 08.04.2025. Verfasst von Christopher Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Canada Research Chairs, Ontario Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoarthritis (OA) is a common chronic inflammatory joint disease, in which innate immunity plays a pivotal role in pathogenesis. Anti-interleukin-1(IL-1) therapies have shown inconsistent results in clinical trials, potentially due to a mismatch in the spatial and temporal dynamics of interleukin-1beta (IL-1β) production and therapeutic interventions. To address this issue, we developed a novel IL-1β “sticky-trap” utilizing cell and gene-based technologies from our lab and evaluated its efficacy in reducing osteoarthritis progression using a murine destabilization of the medial meniscus (DMM) OA model and a compact bone-derived mesenchymal stromal cell (MSC)-based gene expression system. The extracellular domain of interleukin-1 receptor 2 (IL1R2) was employed to design the sticky IL1R2 trap (stkIL1R2). A murine compact bone-derived MSC line was engineered for gene delivery. Although stkIL1R2 was undetectable in the engineered MSC supernatants by enzyme-linked immunosorbent assay (ELISA) and Western blot, it was localized on the cell surface and extracellular matrix (ECM) and demonstrated specific binding to IL-1β using a fluorescent protein-fused binding assay. Doxycycline (Dox)-induced expression of stkIL1R2 significantly inhibited lipocalin-2 (LCN2) expression which is a biomarker of IL-1β activity. For in vivo experiments, 5 × 10 4 Dox-inducible stkIL1R2f expressing MSCs were injected into the knee joints of DMM mice. Bioluminescence imaging revealed MSC survival in the knee joints for up to 7 weeks post-injection. Histological analyses at 10 weeks post-injection, including Safranin-O and Masson trichrome staining, showed that stkIL1R2 treated joints exhibited significantly less cartilage degradation and synovitis compared to controls, as assessed by Osteoarthritis Research Society International (OARSI) scoring of the femur, tibia, and synovium. Moreover, stkIL1R2 treatment reduced matrix metalloproteinases-13 (MMP-13) positive cells and collagen type II degradation in the affected joints. In conclusion, we developed a MSC line expressing an inducible IL1 sticky-trap, which localized to the cell surface and ECM and specifically bound IL-1β. These engineered MSCs survived in normal and DMM knee joints for up to 7 weeks and significantly delayed OA progression and inflammation in the murine model. This study introduces a promising therapeutic approach to combat OA progression.

Schlagwörter

Stichwörter der Autor:innen

cell-based gene therapyinterleukin-1 receptor 2interleukin-1betamesenchymal stromal cellosteoarthritissticky biologics

Autor:innen und Institutionen

  • Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
  • Department of Obstetrics and Gynaecology and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Australian Regenerative Medicine Institute, Monash University, Melbourne, VIC, Australia.

Förderung

  • Canadian Institutes of Health Research
  • Canada Research Chairs
  • Ontario Research Foundation

Zitieren

APA

Kim, C., Li, B., Nakamura, S., Neely, E. J., Rockel, J. S., Oussenko, T., Zhang, P., Kapoor, M., & Nagy, A. (2025). Engineered mesenchymal stromal cells with interleukin-1beta sticky-trap attenuate osteoarthritis in knee joints. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1559155

Vancouver

Kim C, Li B, Nakamura S, Neely EJ, Rockel JS, Oussenko T, et al. Engineered mesenchymal stromal cells with interleukin-1beta sticky-trap attenuate osteoarthritis in knee joints. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1559155

BibTeX
@article{Kim2025,
  author = {Kim, Christopher and Li, Biao and Nakamura, Sayaka and Neely, Eric J and Rockel, Jason S and Oussenko, Tatiana and Zhang, Puzheng and Kapoor, Mohit and Nagy, Andras},
  title = {Engineered mesenchymal stromal cells with interleukin-1beta sticky-trap attenuate osteoarthritis in knee joints},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1559155}
}
Kostenlos starten →